Kiromic Biopharma Inc (KRBP) - News Archive

In the realm of oncology, where the fight against cancer is relentless and innovation is paramount, Kiromic BioPharma, Inc. (OTCQB: KRBP) recently published notable findings from its Deltacel-01 clinical trial. With the...

In a significant development for the biotechnology sector, Kiromic BioPharma, Inc. (OTCQB: KRBP), a Houston-based company specializing in the development of next-generation immunotherapies, has announced the settlement...

Harnessing Innovation: Kiromic BioPharma’s Deltacel Trial Shows Promise Amid Financial Struggles In a landscape where innovation competes fiercely with financial stability, Kiromic BioPharma, Inc. (OTCQB: KRBP) is makin...

In an exciting development for oncology and immunotherapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) announced favorable updates regarding its Deltacel-01 clinical trial, which is assessing the safety and efficacy of Deltac...

Houston, TX - In a significant move to advance cancer therapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced the activation of the University of Arizona Cancer Center (UACC) as the fifth clinical trial site for th...

CSIMarket.com Kiromic BioPharma, Inc. recently received a unanimous recommendation from their Safety Monitoring Committee (SMC) to progress the Deltacel-01 clinical trial to its expansion phase. The study focuses on the...

Kiromic BioPharma s Deltacel: A Promising Leap in the Fight Against Metastatic Lung Cancer with FDA Fast Track Designation In a significant advancement for oncology, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced t...

HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) (Kiromic or the Company) Provides Update on Part 1 of the Deltacel-01 Trial Kiromic BioPharma, Inc., a leading biotechnology company, has announced promising interim resul...

Kiromic BioPharma Reports Promising Interim Results in Phase 1 Deltacel-01 Trial for Advanced NSCLC Patients Houston-based biotech firm Kiromic BioPharma, Inc. (OTCQB: KRBP) has released interim results that are near th...

Kiromic BioPharma (OTCQB: KRBP) has reported a series of promising developments from its Deltacel-01 Phase 1 clinical trial, which is focused on evaluating Deltacel (KB-GDT-01), the Company s allogeneic, off-the-shelf,...

Houston, TX Kiromic BioPharma, Inc. (OTCQB: KRBP) an emerging leader in the field of immuno-oncology recently announced encouraging results from the ongoing Deltacel-01 Phase 1 clinical trial. The trial is focused on ev...

Kiromic BioPharma Advances Deltacel-01 Clinical Trial to Expansion PhaseHouston-based biopharmaceutical company, Kiromic BioPharma, Inc., has announced its plans to advance the Deltacel-01 Phase 1 clinical trial to the...

In the rapidly evolving biotechnology industry, Kiromic Biopharma Inc has struggled to keep pace with the overall market performance this year. This article examines several events that have impacted the company s finan...

Kiromic BioPharma, a biotechnology company, has released positive updates on its ongoing Deltacel-01 Phase 1 clinical trial. The trial aims to evaluate the efficacy of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf,...

Kiromic BioPharma, a leading biotechnology company, has recently announced encouraging six-month follow-up results from the first patient enrolled in their groundbreaking Deltacel-01 Phase 1 clinical trial. This trial a...

for CSIMarket.com :Houston-based biopharmaceutical company, Kiromic BioPharma, has announced favorable safety, tolerability, and early efficacy results in the fourth patient of their Deltacel-01 Phase 1 clinical trial....